Physician profile
Andras Neumark
NPI 1790757482
$381.75
in general payments reported to CMS, 2019-2025
13 companies · $38.05 in 2025
The $38.05 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $197 · 2022: $34.22 · 2023: $98.88 · 2024: $13.62 · 2025: $38.05.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $151.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $150.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $89.41 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals Lp | $60.42 | 2019-2023 | Farxiga |
| Glaxosmithkline, LLC. | $40.64 | 2019 | |
| Pfizer INC. | $37.87 | 2019 | |
| Mylan Specialty L.P. | $24.82 | 2019 | |
| Exact Sciences Corporation | $23.81 | 2023 | Cologuard Collection Kit |
| Lilly USA, LLC | $18.73 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $16.35 | 2019 | |
| Amgen INC. | $16.06 | 2025 | Repatha |
| Kowa Pharmaceuticals America, INC. | $15.99 | 2019 | |
| Astellas Pharma US INC | $13.97 | 2019 | |
| Sunovion Pharmaceuticals INC. | $12.54 | 2019 | |
| Boston Scientific Corporation | $11.14 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andras Neumark listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.